Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producingAntimicrobial agents and chemotherapy · 2025
   Article
2. Evaluation of temocillin efficacy against KPC-2-producing Klebsiella pneumoniae isolates in a hollow-fibre infection model.The Journal of antimicrobial chemotherapy · 2024
   Article
3. Temocillin Resistance in the Enterobacter cloacae Complex Is Conferred by a Single Point Mutation in BaeS, Leading to Overexpression of the AcrD Efflux Pump.Antimicrobial agents and chemotherapy · 2023
   Article
4. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023
   Review
5. Assessing Clinical Potential of Old Antibiotics against Severe Infections by Multi-Drug-Resistant Gram-Negative Bacteria Using In Silico Modelling.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
6. RETRACTED: An Overview of Antimicrobial Stewardship Optimization: The Use of Antibiotics in Humans and Animals to Prevent Resistance.Antibiotics (Basel, Switzerland) · 2022
   Review
7. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.Journal of clinical medicine · 2021
   Review
8. Activity of temocillin and comparators against urinary Escherichia coli and Klebsiella pneumoniae from Iran.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
   Article
9. Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
   Article
10. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clinical microbiology reviews · 2018
    Review
11. Pharmacokinetics and Pharmacodynamics of Temocillin.Clinical pharmacokinetics · 2018
    Review
12. Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer β-Lactam-β-Lactamase Inhibitor Combinations.Journal of clinical microbiology · 2016
    Article
13. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.Frontiers in microbiology · 2016
    Review
14. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Article
15. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.Antimicrobial agents and chemotherapy · 2015
    Review
16. Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens.Infection & chemotherapy · 2014
    Review
17. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Expert opinion on pharmacotherapy · 2014
    Review
18. A new strategy to fight antimicrobial resistance: the revival of old antibiotics.Frontiers in microbiology · 2014
    Review
19. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.The Lancet. Infectious diseases · 2013
    Review
20. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.Clinical microbiology reviews · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as